Consensus of Chinese experts on cardiovascular MRI in evaluating immune-related adverse cardiac events associated with immune checkpoint inhibitors for malignant tumors
In recent years,cancer immunotherapy,particularly immune checkpoint inhibitors(ICIs),has emerged as a significant breakthrough in the treatment of malignant tumors,substantially improving patient outcomes.However,the potential of ICIs to trigger immune-related adverse events(irAEs),including cardiovascular toxicity,poses a significant challenge to cancer immunotherapy.Although the incidence is low,the mortality rate is high.With the increasing use of ICIs,cases of cardiovascular irAEs are on the rise,necessitating the attention of both imaging and clinical physicians.MRI,with its high sensitivity and resolution,plays a pivotal role in the detection and assessment of cardiovascular irAEs.Early diagnosis and evaluation of cardiovascular irAEs through MRI are crucial for patient treatment and prognosis.However,there is currently a lack of unified standardized consensus in China regarding MRI examination and diagnosis of cardiovascular irAEs caused by ICIs.To address this issue,the Molecular Imaging Group,Magnetic Resonance Group,and Cardiothoracic Group of the Radiology Branch of the Chinese Medical Association,in collaboration with the Editorial Board of Chinese Journal of Magnetic Resonance Imaging,have developed a consensus on MRI examination protocols and diagnostic reporting for cardiovascular system irAEs induced by ICIs.This consensus aims to provide a scientific basis for imaging and clinical physicians and to promote the application of MRI technology in the diagnosis of cardiovascular system irAEs.
magnetic resonance imagingimmune checkpoint inhibitorscardiac events associated with Immune checkpoint inhibitorsclinical applicationexpert consensus
万方数据
维普
